| Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms (NCT05987956) | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | 2026-03-18 |
| Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix (NCT07182838) | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 2025-09-12 |
| Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms (NCT07145333) | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 2025-08-12 |
| Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms (NCT01064466) | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 2025-07-16 |
| Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms (NCT06062810) | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 2025-06-21 |
| Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers (NCT07033585) | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 2025-06-15 |
| Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix (NCT03305341) | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 2025-05-18 |
| Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV (NCT06959563) | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 2025-04-28 |
| Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms (NCT03348670) | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 2023-08-18 |
| Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating CEA Positive Rectal Cancer (NCT02403505) | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | 2021-12-28 |